AXSM Jan 2025 30.000 call
| Previous Close | 47.78 |
| Open | 47.78 |
| Bid | 50.30 |
| Ask | 54.30 |
| Strike | 30.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 47.78 - 47.78 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 16 |
GlobeNewswireAxsome Therapeutics Recognizes May as Mental Health Awareness Month
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living wit
Insider Monkey15 Most Black States in the US
In this article, we will be taking a look at the 15 most black states in the US. If you do not want to learn about the demographics of global black population, head straight to the 5 Most Black States in the US. Overview of the Global Black Population: Demographics, Trends, and Immigration Patterns The […]
- GlobeNewswire
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative p
